LGM
APLS

Logos Global Management’s Apellis Pharmaceuticals APLS Stock Holding History

Logos Global Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000,000
Closed -$25.1M – 68
2025
Q4 		$25.1M Hold
1,000,000
– – 1.52% 22
2025
Q3 		$22.6M Hold
1,000,000
– – 2.03% 21
2025
Q2 		$17.3M Buy
+1,000,000
New +$18.5M 1.92% 20
2024
Q4 		– Sell
-1,000,000
Closed -$28.8M – 49
2024
Q3 		$28.8M Sell
1,000,000
-1,000,000
-50% -$37M 3.11% 13
2024
Q2 		$76.7M Buy
+2,000,000
New +$90.6M 6.17% 3
2024
Q1 		– Sell
-1,000,000
Closed -$59.9M – 58
2023
Q4 		$59.9M Buy
1,000,000
+350,000
+54% +$17.8M 5.59% 4
2023
Q3 		$24.7M Buy
+650,000
New +$28.6M 3.3% 9

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Logos Global Management's APLS Position: Q1 2025 in Review

Logos Global Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 500,000 shares — an estimated $16M sold.

Logos Global Management first reported a position in APLS in Q4 2019 and held it in 16 quarters. The position peaked at $88.8M in Q3 2022. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • Logos Global Management reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Logos Global Management sold 500,000 Apellis Pharmaceuticals shares in Q1 2025, an estimated $16M.
  • Logos Global Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 16 quarters.
  • Logos Global Management's Apellis Pharmaceuticals position peaked at $88.8M in Q3 2022.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.